Stay updated on Adjuvant Cisplatin, Radiation & Pembrolizumab Clinical Trial
Sign up to get notified when there's something new on the Adjuvant Cisplatin, Radiation & Pembrolizumab Clinical Trial page.

Latest updates to the Adjuvant Cisplatin, Radiation & Pembrolizumab Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedRevision: v3.4.2 is now shown, replacing v3.4.1; no study data or essential functionality appear to be affected. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check20 days agoChange DetectedInternal site revision updated from v3.4.0 to v3.4.1 with no visible changes to study information or user interface. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check27 days agoChange DetectedShow glossary and QC-related metadata were added (Last Update Submitted that Met QC Criteria, No FEAR Act Data) and Revision: v3.4.0, while the prior labels (Last Update Submitted that met QC Criteria, No FEAR Act data) and Revision: v3.3.4 were removed.SummaryDifference0.2%

- Check42 days agoChange DetectedThe page footer now displays Revision: v3.3.4, replacing the prior Revision: v3.3.3. This is a minor maintenance update that does not alter the study content, endpoints, or user-facing functionality of the page.SummaryDifference0.1%

- Check63 days agoChange DetectedAdded a Locations section listing Kentucky, Michigan, Ohio, South Carolina, and Texas. Removed the HHS Vulnerability Disclosure link and updated the page revision to v3.3.3.SummaryDifference0.7%

- Check92 days agoChange DetectedRevision history updated from v3.2.0 to v3.3.2 on the page.SummaryDifference0.1%

Stay in the know with updates to Adjuvant Cisplatin, Radiation & Pembrolizumab Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Adjuvant Cisplatin, Radiation & Pembrolizumab Clinical Trial page.